Impact of anti-osteoporosis medication on refracture prevention following osteoporotic vertebral fracture: a systematic review and meta-analysis
Authors' conclusion
Teriparatide may be considered a preferred option for secondary fracture prevention in patients with OVFs.
Study context
- Population
- Adult patients with existing osteoporotic vertebral fractures33 studies
- Comparison
- Anti-osteoporosis medications vs control or each other
- Outcome
- Refracture prevention (subsequent vertebral fracture)
Methodological detailsPRISMA
- PRISMA
Pooled result
As reported in the abstract
Subsequent vertebral fracture (VF) rates
Odds ratio (95% CI)
Bisphosphonatesvs Control1 year
0.29(0.20–0.43)
Bisphosphonatesvs Control3 years
0.51(0.42–0.62)
Bisphosphonatesvs Controlfinal follow-up
0.35(0.26–0.48)
Teriparatidevs Control
0.39(0.16–0.97)
Teriparatidevs Bisphosphonates
0.41(0.30–0.56)
Romosozumabvs Bisphosphonatespatients undergoing vertebral augmentation
0.21(0.09–0.51)
Further pooled results
| Outcome | Estimate | |
|---|---|---|
| BMD percent changeBisphosphonatesvs Control1 year | MD 3.65 (95% CI 2.63–4.67) | |
| BMD percent changeBisphosphonatesvs Control2 years | MD 5.39 (95% CI 3.87–6.92) | |
| BMD percent changeBisphosphonatesvs Control3 years | MD 5.44 (95% CI 4.38–6.51) | |
| VAS scoresBisphosphonatesvs Control6 months | MD −0.41 (95% CI −0.67 to −0.14) | |
| VAS scoresBisphosphonatesvs Control12 months | MD −0.92 (95% CI −1.25 to −0.59) | |
| VAS scoresTeriparatidevs Bisphosphonates3 months | MD −1.41 (95% CI −2.47 to −0.35) | |
| ODI scores · 12 monthsBisphosphonatesvs Control | SMD −1.89 (95% CI −3.07 to −0.71) | |
| RMDQ scores · 3 monthsVitamin Dvs Control | MD −1.59 (95% CI −2.88 to −0.31) | |
| −50510Difference (linear scale) |
Original publication
Impact of anti-osteoporosis medication on refracture prevention following osteoporotic vertebral fracture: a systematic review and meta-analysis. Osteoporos Int. Published 22 August 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →